AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle Muscular Dystrophy: Likelihood of Approval
AB-1003 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Limb-Girdle Muscular Dystrophy. According to GlobalData, Phase II drugs for Limb-Girdle Muscular Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AB-1003 LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.AB-1003 overviewAB-1003 is under development for the treatment of limb-girdle muscular dystrophy. It comprises of an adeno-associated virus. The drug candidate is developed based on adeno-associated virus vector (AAV) technology. It is administered by intravenous route.Asklepios BioPharmaceutical overviewAsklepios BioPharmaceutical (AskBio) is AAV gene therapy development company that develops and markets novel protein and cellular based therapies. Its product pipeline includes therapies for the treatment of neuromuscular, central nervous system, heart related diseases including pompe, limb-girdle 2i, huntington’s, epilepsy, parkinson’s, and congestive heart failure (nanocor). AskBio has developed library of AAV biological nano particles that provides unsurpassed transduction. It serves pharmaceutical and biotechnology companies. AskBio is headquartered in Durham, North Carolina, the US. For a complete picture of AB-1003's drug-specific PTSR and LoA scores, buy the report here.
AB-1003is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Limb-Girdle Muscular Dystrophy.
What's Your Reaction?
